Healthcare / BiotechnologyNasdaqGS
$5.43
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
2/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$435M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-57.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-158.3M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | — | — | — | — | — | $351.4M | $48.6M | — | — |
| Net Income | $-158.3M | $-158.3M | $-168.4M | $-136.0M | $-115.9M | $121.2M | $-10.9M | $-14.0M | $-9.1M |
| EBITDA | $-180.5M | $-180.5M | $-192.5M | $-163.7M | $-130.4M | $138.4M | $-11.0M | $-14.6M | $-9.5M |
| EPS | -1.94 | -1.94 | -2.00 | -1.63 | -1.39 | 1.37 | -0.51 | -1.39 | — |
| Operating Margin | — | — | — | — | — | 39.4% | -22.7% | — | — |
| Net Margin | — | — | — | — | — | 34.5% | -22.5% | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | — | — | — | — | $-122.9M | $-87.0M | $296.7M | $-12.8M | $-7.9M |
| Returns | |||||||||
| ROE | -57.5% | -57.5% | -38.4% | -24.5% | -18.1% | 17.1% | -2.0% | 28.3% | 25.1% |
| Growth & Yield | |||||||||
| Revenue Growth | — | — | — | — | — | 622.5% | — | — | — |
| EPS Growth | 3.0% | 3.0% | -22.7% | -17.3% | -201.5% | 368.6% | 63.3% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.